[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1994

Dermatology and the Evolution of Therapies to Control Inflammatory Tissue Injury

Author Affiliations

Section of Dermatology Department of Medicine University of Chicago 5841 S Maryland MC 5067 Chicago, IL 60637

Arch Dermatol. 1994;130(6):781-782. doi:10.1001/archderm.1994.01690060111016
Abstract

INFLAMMATORY CELL-MEDIATED tissue injury is a final common pathway in the pathogenetic mechanisms of many skin diseases. Dermatologic observations and investigative studies on a wide variety of therapeutic agents and modalities, which have anti-inflammatory efficacy, have often pioneered in discovering new directions and understanding about the control of such inflammatory tissue injury. In addition to their practical usefulness in the treatment of skin diseases, these dermatologic contributions have had applications in the treatment of a variety of other medical disorders, especially those in which complement activation via either the classic or alternative pathway activates neutrophilic tissue injury as occurs, for example, in a number of vasculitides and rheumatoid arthritis. It is likely that many further opportunities for their beneficial exploitation await wider medical exploration.

Dermatologists were the first to recognize that certain antimicrobial agents had anti-inflammatory pharmacologic activity unrelated to their antibacterial activity. Sulzberger1 in 1939 reported the successful

First Page Preview View Large
First page PDF preview
First page PDF preview
×